Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Deek

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Current Oncology (Toronto, Ont.)|July 28, 2023
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing ResearchRitesh Kumar, Jongmyung Kim, Matthew P Deek, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2019
Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins ExperienceMatthew P Deek, Colburn Yu, Ryan Phillips, et al.
The Prostate|July 18, 2024
PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancerPhilip Sutera, Jongmyung Kim, Ritesh Kumar, et al.
The Prostate|June 3, 2022
Genomic biomarkers to guide precision radiotherapy in prostate cancerPhilip Sutera, Matthew P Deek, Kim Van der Eecken, et al.
Journal of Gastrointestinal Oncology|January 24, 2022
Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapyShane S Neibart, Swati Mamidanna, Anupama Chundury, et al.
Pancreas|January 13, 2018
Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant ChemoradiationJoseph M Herman, Salma K Jabbour, Steven H Lin, et al.
World Journal of Urology|September 8, 2018
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatmentC Leigh Moyer, Ryan Phillips, Matthew P Deek, et al.
European Urology Oncology|June 16, 2020
Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate CancerMatthew P Deek, Kekoa Taparra, Ryan Phillips, et al.
Prostate Cancer and Prostatic Diseases|January 11, 2022
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomicsPhilip Sutera, Kim Van Der Eecken, Amar U Kishan, et al.
International Journal of Radiation Oncology, Biology, Physics|August 18, 2020
Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate CancerMatthew P Deek, Kekoa Taparra, Dyda Dao, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Current Oncology (Toronto, Ont.)|July 28, 2023
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing ResearchRitesh Kumar, Jongmyung Kim, Matthew P Deek, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2019
Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins ExperienceMatthew P Deek, Colburn Yu, Ryan Phillips, et al.
The Prostate|July 18, 2024
PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancerPhilip Sutera, Jongmyung Kim, Ritesh Kumar, et al.
The Prostate|June 3, 2022
Genomic biomarkers to guide precision radiotherapy in prostate cancerPhilip Sutera, Matthew P Deek, Kim Van der Eecken, et al.
Journal of Gastrointestinal Oncology|January 24, 2022
Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapyShane S Neibart, Swati Mamidanna, Anupama Chundury, et al.
Pancreas|January 13, 2018
Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant ChemoradiationJoseph M Herman, Salma K Jabbour, Steven H Lin, et al.
World Journal of Urology|September 8, 2018
Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatmentC Leigh Moyer, Ryan Phillips, Matthew P Deek, et al.
European Urology Oncology|June 16, 2020
Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate CancerMatthew P Deek, Kekoa Taparra, Ryan Phillips, et al.
Prostate Cancer and Prostatic Diseases|January 11, 2022
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomicsPhilip Sutera, Kim Van Der Eecken, Amar U Kishan, et al.
International Journal of Radiation Oncology, Biology, Physics|August 18, 2020
Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate CancerMatthew P Deek, Kekoa Taparra, Dyda Dao, et al.
Pageof 8